Infant Data
Results
INDICATIONS
- Treatment of patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. Also indicated as a replacement therapy.
- For patients beginning warfarin therapy (vitamin K antagonist therapy), continue protein C until stable anticoagulation is achieved. Begin warfarin therapy at a low dose and titrate up to desired anticoagulation.
ADVERSE EFFECTS
Excessive doses can cause serious bleeding problems. Hypotension, bradycardia, dyspnea, and transitory flushing have been reported in adults.
ADMINISTRATION
Administer solution at a concentration of 100 international units/mL by IV infusion at a maximum rate of 0.2 mL/kg/minute.
MONITORING
Patients receiving protein C and initiating oral anticoagulant therapy are at increased risk for warfarin-induced skin necrosis. Most serious and common adverse events reported were hypersensitivity or allergic reactions and lightheadedness. Made from human blood. Bleeding episodes were reported in clinical studies. Product contains small amount of heparin. Patients with renal impairment may experience sodium overload (contains greater than 200 mg of sodium in maximum daily dose).